Navigation Links
Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists
Date:12/19/2016

LONDON, Dec. 19, 2016 /PRNewswire/ -- Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

What can be expected from the cholesterol-lowering drugs market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.


Our 199-page report provides 153 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2025? Our study forecasts revenues in the following cholesterol-lowering drugs submarkets and products:

- Statins and Fixed-Dose Combinations

o Crestor

o Lipitor

o Livalo

o Lescol/Lescol XL

o Zocor

o Vytorin

o Caduet

o Other Statins and Fixed-Dose Combinations (grouped forecast)

- Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs

o Zetia

o Welchol

o Tricor

o Other cholesterol-lowering drugs (grouped forecast)

- PCSK9 Inhibitors

o Praluent

o Repatha

o RN316

o Other PCSK9 Inhibitors (grouped forecast)

- Novel Cholesterol-Lowering Drugs

o Juxtapid

o Kynamro

o MK-0859

o Other novel cholesterol-lowering drugs (grouped forecast)

See revenue forecasts for the leading international markets

How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:

- US

- Japan

- Germany

- France

- Italy

- Spain

- UK

- China

- Brazil

- Russia

- India

Leading companies and potential for market growth

Overall revenue for the cholesterol-lowering drugs market will reach $24.63bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. Shifts in diets and lifestyles will contribute to rising levels of high cholesterol, while highly disruptive new treatments will revitalise the market

Our work analyses the key companies in the market. See visiongain's analysis of 9 leading companies, including these:

- AstraZeneca

- Merck

- Pfizer

- Kowa

- Daiichi Sankyo

- Abbvie

- Novartis

- Sanofi

- Amgen


A company profile gives you the following information where available:

- Discussion of a company's activities and outlook

- Analysis of products currently on the market as well as pipeline products

- Company news relevant to the market

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Cholesterol-Lowering Drugs industry?

Our new report discusses issues and events affecting the cholesterol-lowering drugs market. You will find discussions, including qualitative analyses:

- Highly disruptive treatments entering the market

- Increasing potential in both established and emerging markets

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Cholesterol-Lowering Drugs Market Forecast 2015-2025 report helps you


In summary, our 199-page report gives you the following knowledge:

- Revenue forecasts to 2025 for the Cholesterol-Lowering Drugs market – discover the industry's prospects, finding promising places for investments and revenues

- Revenue forecasts to 2025 for submarkets in each – statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs

- Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5 and BRIC

- Assessment of 9 leading companies – analysis of cholesterol-lowering products, revenue, news and upcoming product releases

- Discussion of what stimulates and restrains companies and the market

- Prospects for established firms and those seeking to enter the market

Download the full report: https://www.reportbuyer.com/product/3516952/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cholesterol-lowering-drugs-market-forecast-2015-2025-opportunities-in-pcsk9-inhibitors-cetp-inhibitors-mttp-inhibitors-apob-inhibitors-and-ppar-agonists-300381445.html


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Cholesterol-lowering Drugs Market Forecast 2015-2025
2. Prime Therapeutics studies find cholesterol-lowering statins are underused
3. Express Scripts Includes Innovative Cholesterol-Lowering Drugs on National Preferred Formulary
4. Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data
5. Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA
6. Immunotherapy Drugs Market Worth 201.52 Billion USD by 2021
7. Cancer Drugs in the FDA Fast Lane: Analytical Tool
8. CPhI SEA, Jakarta: the Platform of Choice for Halal Drugs
9. The Cost of Specialty Drugs: Payer perspectives
10. 2017-2021 Drugs of Abuse Testing: France, Germany, Italy, Spain, UK--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
11. Pulmonary Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... CAESAREA, Israel , May 4, 2017  DarioHealth ... with mobile health and big data solutions, today announced ... an A&D Company, and STI Technologies Limited to lower ... effective immediately. Through STI,s innoviCares card, which is available ... , DarioHealth customers will be eligible for additional ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... 2017  George Clinical, a leading full-service CRO in ... Vector Oncology, a Memphis -based ... today that George Clinical has acquired Vector Oncology,s Pharma Services ... dual purpose of strengthening the ability of George ... solutions throughout the Asia-Pacific , ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... 2017 , ... Pot. Reefer. Grass. Mary Jane. No matter what people call ... like never before. More than a map, new social marketplace Weedable goes ... – and for the first time – each other. A social marketplace like no ...
(Date:5/21/2017)... ... ... Following the tragic and widely publicized death of Rory Staunton, 12, from ... follow a protocol to quickly identify and treat the condition. , The mandate ... have saved Rory or anyone else’s life. , Now, five years after the ...
(Date:5/19/2017)... ... May 19, 2017 , ... DMG Productions is ... of Innovations with Ed Begley, Jr., airing fourth quarter 2017 on FOX Business. ... clean, organic dietary supplement made from naturally occurring ingredients. Innovations will enlighten viewers ...
(Date:5/19/2017)... , ... May 19, 2017 , ... ... services and retirement planning assistance to families and business owners in the region, ... to advocate for MS sufferers and their families. , Multiple sclerosis (MS) is ...
(Date:5/19/2017)... ... May 18, 2017 , ... ML Billing, 2016 Billing Company of the ... specializes in large group practices, is pleased to announce their 30th anniversary. Not only ... the standard in all aspects of full-service medical billing. This has allowed ML Billing ...
Breaking Medicine News(10 mins):